# IDENTIFICATION OF POTENTIAL ANTI-TUMORIGENIC TARGETS FOR ROSEMARY COMPONENTS USING DUAL REVERSE SCREENING APPROACHES

*SAVITA DESHMUKH*[*1], SHIVAKUMAR B MADAGI[2], VIPRA SAVADATTI[3]*

*[1*, 2, 3] Department of Bioinformatics, Karnataka State Women's University, Bijapur-586108, Karnataka, INDIA.*
**Corresponding Author Email:** savitajayarao@gmail.com

## ABSTRACT

*Introduction:* Pioneering research on the role of phytochemicals for the treatment of various ailments in the traditional medicines has highlighted rosemary as one of the promising plant for cancer prevention and treatment. The anti-neoplastic properties of rosemary can be attributed to its major bioactive components like Carnosol, Carnosic acid (CA), Ursolic acid (UA), Rosmarinic acid (RA), Rosmanol and other diterpenes. However, only few targets for these bioactive components have identified. *Objectives:* (1) To identify the molecular targets for carnosol, carnosic acid, rosmarinic acid and ursolic acid.(2)To classify the targets based on their action as anti-inflammatory, anti-apoptotic, signal transduction modulators, antioxidants, antimutagenic, etc. (3) To find the experimental proofs for the each bioactive component and the target. *Material and Methods:* The putative target identification was done by dual virtual reverse screening approach with the help of two servers namely, PharmMapper and idTatget. The target proteins with anti-neoplastic acivity ranked by fit score and binding energy were obtained and were classified based on their action. The targets obtained were validated from experimental studies. *Results:* The potential ani-neoplastic targets identified from both the servers were experimentally verified. The study also identified targets for rosemary components which are anti-neoplastic in nature but the experimental proof of their interaction with these components was not studied invivo. *Conclusion:* The present work using dual inverse screening strategy has revealed anti-tumorigenic targets for 4 bioactive components of rosemary. It also provides tractable set of anti-cancer targets for these components which can be further validated by invivo and invitro study.

## KEY WORDS

*Anti-tumorigenic targets, molecular targets, reverse screening, rosemary.*

## INTRODUCTION

Of the drugs prescribed for cancer treatment majority of them are chemopreventive phytochemicals derived from traditional herbs[1]. The Southeast Asian countries are less prone to different types of cancers due to their dietary habits involving curcumin, onion, garlic, ginger, cruciferous vegetables, tomatoes, chilies etc. that suppress the transformative, hyper proliferative and inflammatory processes that initiate carcinogenesis[2]. The anti-cancer activities of these plants are due to the presence of active components like Curcumin (diferuloylmethane) in Turmeric, Zerumbone in Ginger, isothiocyanates, indole-3-carbinol, isoflavones, protease inhibitors, saponins, phytosterols, inositol hexaphosphate, vitamin C, d-limonene, lutein, folic acid, β-carotene, lycopene, selenium from different types of fruits and vegetables[3].

Rosemary (*Rosmarinus officinalis* L.) a member of Lamiaceae has been studied in the last decade

for many of its therapeutic effects on cenral nervous system (CNS), circulation, hepatoprotective effects, anti-tumorigenic effects etc., its chemo preventive effect is most widely studied[4]. Many researchers have shown its chemopreventive properties on neoplastic cells and experimental evidence indicating towards the anti-carcinogenic and antitumor activities both in *invitro* and *invivo* platforms [5-10, 17-20]. Rosemary's bioactive components include phenolic diterpenes or triterpenes, flavonoids and phenolic acids[8] such as carnosic acid (CA), carnosol, ursolic acid (UA), caffeic acid, betulinic acid, rosmaridiphenol, rosmanol and rosmarinic acid (RA). The antitumor activities of the rosemary constituents are reported for carnosol, CA, UA and RA[9], which have shown to inhibit tumor formation and promotion stages of tumorigenesis[5, 10, 11-13]. The antioxidant and anti-inflammatory properties of the rosemary help the cells of the body to protect from damage. A study conducted on rosemary as a preclinical perspective has revealed that effects of rosemary are not species specific as its effects are consistent both in human cell lines and rodent models[9]. Rosemary has shown to suppress or block pro-inflammatory pathways in different cancer cells[3]. Its extracts have been studied for its antitumor or antineoplastic activities on different types of cancer cell lines/ rat or mice models and only one on human[9]. The probable mechanism for rosemary polyphenols in cancer prevention or progression has been revealed as arresting cell cycle at multiple phases, inhibition of tumor promoting pathways or by inducing cancer preventive markers. Many invivo studies have reported some of the molecular targets for rosemary components for their antioxidant, anti-inflammatory, antiapoptotic targets, signal transduction modulators, antimutagenic and epigenetic activity[3-5, ,9,11-14, 21-22]. Here in this study, we have

characterized major pharmacological therapeutic targets to which bioactive components of rosemary bind.

In the present work, we have used comparative study of two reverse screening servers namely PharmMapper and the idTarget to identify the potential anti-tumorigenic targets for rosemary components. Both are open-source online servers which fishes putative therapeutic targets for the given molecule. PharmMapper uses reverse pharmacophore mapping strategy where as idTarget perform divide and conquer approach to predict possible binding targets. Thus dual reverse screening strategy was used to identify the potential anticancerous and anti-tumorigenic targets for the bioactive active components of the rosemary. Reverse screening approach searches a protein database against a given molecule. It involves reverse docking and Pharmacophore mapping which is gaining as quick and computationally rigorous alternative to fish molecular targets.The components of the rosemary bind to many therapeutic targets when searched through Reverse Pharmacology approach using PharmMapper and idTargets. In this study, we have identified and also classified the targets as antimutagenic, anti-inflammatory, antioxidant and signal transducing modulator for four of the rosemary components namely, carnosic acid, rosmarinic acid, carnosol and ursolic acid. The purpose of this work was to identify the potential targets for the bioactive components of rosemary that would help to predict the mechanism of their anti-neoplastic activity *invivo*. Recently several inverse docking tools have been reported such as INVDOCK[15], Tarfisdock[16], PharmaMapper[17], idTarget[18], Inverse Screening @tome server[19]. One such approach was used to identify the potential anti-neoplastic targets of tea polyphenols such as epigallocatechin gallate (EGCG), epigallocatechin

(EGC), epicatechin gallate (ECG) and epicatechin (EC) [20]. In this work we have taken the targets from PharmaMapper and idTargets to analyse the anti-cancerous activity of rosemary bioactive components. The present work has identified anti-tumorigenic targets for 4 bioactive components of rosemary and also provides tractable set of anti-cancer targets for these components which can be further validated by *invivo* and *invitro* study.

## MATERIALS AND METHODS

### Retrieval of 3D Structures of Rosemary Polyphenols

The three dimensional structures of four components of rosemary namely carnosol, carnosic acid, RA and UA were retrieved from PubChem's database with pubChem IDs CID 442009, CID 65126, CID 5281792 and CID 64945 respectively. The .sdf file formats were then converted to .mol2 using MarvinSketch. This step was essential for both PharmMapper and idTarget servers to predict the molecular targets for active components prior to submission. The .mol2 files were then submitted to both PharmMapper and idTarget for the identification of possible therapeutic targets for each of these components.

### Potential Therapeutic Target Identification Using PharmMapper and idTarget

The PharmMapper is a web server (http://59.78.96.61/pharmmapper) that identifies potential target candidates for the given small molecule. During submission a maximum of 300 conformation generations were chosen and only human target set were considered to perform Genetic Algorithm (GA). The pharmocophore targets were then analysed based on the fit score. The idTarget, is also a web server (http://idtarget.rcas.sinica.edu.tw) which predicts possible binding of targets of a small chemical molecule via a divide and conquer docking approach. The idTarget reported an average of 7000 molecular targets for each of these components.

## RESULTS AND DISCUSSION



**Figure 1. Structure of rosemary components Carnosol, CA, Rosmanol, UA and RA.**

The bioactive components studied for anti-cancer targets in this study include carnosol, carnosic acid (CA), ursolic acid (UA) and rosmarinic acid (RA) as shown in **Figure 1**. PharmMapper listed top 300 targtes based on the fit score for each of the component of rosemary. The idTarget server predicted 7527 targets for carnosol, 7535 for CA, 7526 targets for RA and 7278 for UA. Since idTarget server docks given molecule with whole set of PDB database only targets that are predicted by both PharmMapper and idTarget were considered for further analysis.

### Potential Anti-tumorigenic Targets for Carnosol

Carnosol is a ortho-diphenolic diterpene which constitutes approximately 5% of the dry weight of the rosemary. Carnosol has been widely studied for its anti-cancer activities [6, 7, 11-14].The potential therapeutic targets for carnosol identified by reverse screening procedures were collected from PharmMapper that gives pharmacologically important targtes. The server predicted majority of targets that are proven experimentally for carnosol. Among the target screened, many were involved in anti-tumor activities which can explain the anti-cancer property of carnosol. The targets so obtained were classified based on their functions as antimutagenic, antioxidant, anti-inflammatory, signal transducing modulators, epigenetic and others. The targets were then confirmed by screening the results of targets predicted by idTarget server. Only those targets which are predicted by both the servers were considered since the approaches used by both the servers are different. There were total 80 targets under these categories predicted by both the servers. 25 targets were of Anti-inflammatory; 41 signal transduction modulators; 02 of anti-mutagenic; 01 epigenetic; 05 anti-oxidant atrgtes and 06 other receptors and enzymes involved in cancer.

Potential targets for carnosol identified by reverse screening procedures and experimentally compared data are listed in **Table 1**. Computed binding free energies and experimental references for several carnosol-protein complexes are also included.

Carnosol binds to proteins of MAPK pathway which are the important targets of inflammation. Of the 80 targets that are predicted by both the servers' majority of them were signal transduction modulators which are involved in inflammation, antioxidant and antiapoptotic activities. Experimentally proven targets for carnosol are listed in the **Table 1**. Carnosol inhibits the early inflammation during cancer progress by binding to Mitogen-activated protein kinase 14 a stress related protein kinase , Cell division protein kinase 2 (CDK2) that controls cell division and Mitogen-activated protein kinase 10 involved in cell proliferation[21,22]. It binds to Glucocorticoid receptor which is the potent anti-inflammatory target[23]. The anti-mutagenic experiment have proved the interaction of carnosol with Glutathione S-transferase A1[24]. A study has shown that carnosol acts as an antagonist by binding to ligand binding site of androgen receptor[25]. Carnosol binds to PPARgamma which inhibits the transcriptional activation of COX-2 a protein produced during transformed cells and human malignancies[26]. This target was predicted by PharmMapper and not by idTarget. Carnosol also binds to Leukocyte elastase , Alcohol dehydrogenase, Glutathione-S-transferase-P, NAD(P)H dehydrogenase [quinone], Catheaspin S , Caspase 3, etc which are also therapeutic targets for cancer are not been been predicted by idTarget. Carnosol interaction with these targets are also not been studied till date. The list of anti-tumor targets to which the carnosol binds is shown along with the

references of targets as anti-tumors in the **Table 2.**

**Table 1: Carnosol possible targets found by screening procedures compared with experiment.**

| Target Name | PDB IDs | Predicted by Server | Implicated by Experiment | Energy Score (kcal/mol) | Reference or Related Disease |
|---|---|---|---|---|---|
| Mitogen-activated protein kinase 14 | 1OUY | PharmMapper/ idTarget | Yes | -8.08 | [22] |
| | 2ZB0 | | | -8.9 | |
| | 1ZZL | | | -7.38 | |
| | 1BL7 | | | -8.47 | |
| | 3FC1 | | | -7.45 | |
| | 1ZYJ | | | -8.11 | |
| | 1OZ1 | | | -8.73 | |
| Cell division protein kinase 2 (CDK2) | 1PYE | PharmMapper/ idTarget | Yes | -7.97 | [22] |
| | 3EZR | | | -6.92 | |
| | 1R78 | | | -7.58 | |
| | 2VTP | | | -7.2 | |
| | 2BHE | | | -8.32 | |
| | 1OIQ | | | -7.95 | |
| Androgen receptor | 3B67 | PharmMapper/ idTarget | Yes | -9.21 | [25] |
| | 1GS4 | | | -9.28 | |
| | 1Z95 | | | -9.01 | |
| | 2AX8 | | | -8.67 | |
| Glucocorticoid receptor | 3CLD | PharmMapper/ idTarget | No | -9.23 | Inflammation [23] |
| | 1NHZ | | | -8.42 | |
| | 1M2Z | | | -9.49 | |
| Mitogen-activated protein kinase 10 | 1PMN | PharmMapper/ idTarget | Yes | -8.02 | [22] |
| Glutathione S-transferase A1 | 1GSE | PharmMapper/ idTarget | Yes | -8.06 | [24] |
| | 1GUH | | | -8.45 | |

**Table 2: Other Experimentally proven anti-tumor targets predicted only by ParmMapper to which Carnosol binds**

| Target Name | PDB IDs | Rank | Reference |
|---|---|---|---|
| PPAR gamma | 1RDT | 146 | [26] |
| | 2I4P | 210 | |
| Glutathione-S- Transferase-P (GST-P) | 11GS | 83 | [24] |
| Alcohol dehydrogenase class-3 | 1MA0 | 95 | [27] |
| NAD(P)H dehydrogenase [quinone ]-1 | 1DXO | 142 | [28] |
| Methionine Aminopeptidase | 1BOA | 8 | [29] |
| Leucocyte elastase | 1H18 | 27 | [21] |
| Cathespin S | 1NQC | 140 | [30] |
| Mineralocorticoid Receptor | 2AA5 | 177 | [31] |
| Caspase-3 | 1RHR | 184 | [32] |

| | | | |
|---|---|---|---|
| HSP90 | 1UYH | 69 | [33] |
| Proteooncogene synthase tyrosine ptotein kinase ABL1 | 2HZI | 263 | [34] |
| Tyrosine kinase ITK/TSK | 1SNU | 269 | [35] |
| Baculoviral IAP repeat-containing protein 4 (XIAP) | 1TFQ | 290 | [36] |
| Histone-N-Methyltransferase | 1JQE | 100 | [37] |
| Vascular endothelial growth factor | 1YWN | 113 | [38] |
| Proto-ncogene tyrosine protein kinase src | 1O4A | 221 | [39] |
| Histone deacetylase-8 | 1T64 | 261 | [40] |
| 3-phosphoinositide-dependent protein kinase 1 | 2PE1 | 21 | [41] |
| Cyclin-A2 | 2IW6 | 156 | [42] |

***Potential Anti-tumorigenic Targets for CA, RA and UA***

The anti-cancer properties of other components of the rosemary have also implicated in number of experiments[3-5,8-10]. Therefore the anti-tumor targets for these components were also studied. The potential anti-tumor targets to which CA, RA and UA are listed In the **Table 3**.

**Table 3: Potential anti-tumor targets for Carnosic acid (CA), Rosmarinic acid (RA) and Ursolic acid (UA)**

| Ligand Name | Target Name | PDB ID | Energy Score kcal/mol |
|---|---|---|---|
| CA | Glucocorticoid receptor | 1M2Z | -9.02 |
| | cAMP-specific 3,5-cyclic phosphodiesterase 4B | 1XOS | -8.9 |
| | Mitogen-activated protein kinase 14 | 1OVE | -8.3 |
| | Macrophage metalloelastase | 1ROS | -8.74 |
| | Mineralocorticoid receptor | 2AAX | -9.24 |
| | Proto-oncogene tyrosine-protein kinase LCK | 3BYU | -8.43 |
| | Cell division protein kinase 2 | 1OIR | -8.43 |
| | Caspase-3 | 1NMS | -7.83 |
| | cAMP-specific 3,5-cyclic phosphodiesterase 4D | 1Y2K | -8.92 |
| | Glutathione S-transferase P | 4PGT | -7.79 |
| | Serine/threonine-protein kinase Chk1 | 2E9U | -7.13 |
| | Vascular endothelial growth factor receptor 2 | 2P2I | -8.72 |
| | Interleukin-2 | 1PY2 | -8.34 |
| | Estrogen receptor | 1YIN | -8.91 |
| | Androgen receptor | 1GS4 | -8.8 |
| | 3-phosphoinositide-dependent protein kinase 1 | 1UU9 | -8.26 |
| | Tyrosine-protein phosphatase non-receptor type 1 | 1Q1M | -8.15 |
| RA | Cathepsin K | 1TU6 | -8.47 |
| | Mitogen-activated protein kinase 14 | 3D83 | -8.84 |
| | cAMP-specific 3,5-cyclic phosphodiesterase 4B | 1Y2H | -8.33 |
| | Mitogen-activated protein kinase 12 | 1CM8 | -8.99 |
| | Matrix metalloproteinase-9 | 1GKC | -10.67 |

| | | | |
|---|---|---|---|
| | Ras-related protein Rap-2a | 1KAO | -10.53 |
| | Caspase-3 | 1NMS | -9.52 |
| | 3-phosphoinositide-dependent protein kinase 1 | 2PE2 | -8.19 |
| | Cell division protein kinase 2 | 2C6I | -8.27 |
| | Cell division protein kinase 6 | 1XO2 | -9.7 |
| | ADAM 33 | 1R55 | -8.96 |
| | Glutathione S-transferase P | 4PGT | -7.42 |
| | Glutathione S-transferase Mu 1 | 1XW6 | -8.15 |
| | Glutathione S-transferase A1 | 1GUH | -8.1 |
| | Alcohol dehydrogenase class-3 | 1MC5 | -9 |
| | Mast/stem cell growth factor receptor | 1PKG | -9.93 |
| | Serine/threonine-protein kinase 6 | 1MQ4 | -9.53 |
| | Trifunctional purine biosynthetic protein adenosine-3 | 1MEN | -8.86 |
| | Cellular retinoic acid-binding protein 2 | 1CBS | -8.87 |
| | Serine/threonine-protein kinase Chk1 | 2HOG | -6.31 |
| | Proto-oncogene tyrosine-protein kinase Src | 1O47 | -7.61 |
| | Hypoxanthine-guanine phosphoribosyltransferase | 1HMP | -7.87 |
| | Tyrosine-protein phosphatase non-receptor type 1 | 1ECV | -8.85 |
| | Neprilysin | 1R1J | -9.73 |
| UA | Glutathione S-transferase P | 4PGT | -9.02 |
| | Dipeptidyl peptidase 4 | 2IIV | -9.12 |
| | Mitogen-activated protein kinase 10 | 1PMN | -8.95 |
| | Mitogen-activated protein kinase 14 | 1OVE | -9.32 |
| | Glucocorticoid receptor | 3CLD | -9.85 |
| | Macrophage metalloelastase | 1ROS | -9.05 |
| | cAMP-specific 3,5-cyclic phosphodiesterase 4B | 1XMU | -9.11 |
| | Interleukin-2 | 1QVN | -8.3 |
| | Cell division protein kinase 2 | 1OIR | -9.38 |
| | Calmodulin | 1CTR | -8.3 |
| | 3-phosphoinositide-dependent protein kinase 1 | 2PE1 | -8.91 |
| | Serine/threonine-protein kinase Chk1 | 2AYP | -7.94 |
| | cAMP-specific 3,5-cyclic phosphodiesterase 4D | 1Y2K | -9.23 |
| | Vascular endothelial growth factor receptor 2 | 1Y6B | -8.32 |
| | Proto-oncogene serine/threonine-protein kinase Pim-1 | 2BIK | -9.15 |
| | Epidermal growth factor receptor | 3BEL | -9.11 |
| | Caspase-3 | 1NMS | -8.72 |
| | Proto-oncogene tyrosine-protein kinase LCK | 1QPE | -8.49 |
| | Glutathione S-transferase A1 | 1GUH | -8.8 |
| | Estrogen receptor | 1XP9 | -7.19 |
| | Retinoic acid receptor RXR-alpha | 2P1U | -8.24 |
| | E3 ubiquitin-protein ligase Mdm2 | 1T4E | -9.34 |
| | Tyrosine-protein phosphatase non-receptor type 1 | 1Q6S | -9.39 |

The PharmMapper gives the recurring targets with different PDB id. Therefore the above data has been prepared based on the energy score given by idTarget. Only those targets among

them with highest binding energy were considered. The above data are support the anti-cancer properties of the rosemary components. Many of the targets that are listed are have been experimentally proven for the particular rosemary components.

In this study, dual reverse screening approach was used to identify the potential targets for the bioactive components of Rosemary such as carnosol, CA, RA and UA. The results reveal that the reverse screening using PharmMapper and idTarget has characterized those targets for bioactive components of rosemary many of which are experimentally validated as their anti-neoplastic targets. Firstly the result revealed that targets like MAPK-14, CDK2, AR, PPAR gamma, are the experimentally proven for cancer. Screening also identified targets which are clinical targets with anti-cancer effects or enzymes that are involved in antitumor drug design. This work would help to enlighten on the anti-tumorigenic abilities of the bioactive components of the rosemary. The binding potential of rosemary ingredients to their novel set of potential targets can be further validated by *invivo* and *invitro* bioassays. This new reverse screening approach can be used as an alternative computational strategy to for quick identification of potential therapeutic targets in phytochemicals and medicinal plants.

### ACKNOWLEDGEMENT

### REFERENCES

1. Maria Russo, Carmela Spagnuolo, Idolo Tedesco and Gian Luigi Russo. Phytochemicals in Cancer Prevention and Therapy: Truth or Dare? Toxins. 2010; 2:517-551.

2. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992; 18:1–29.

3. Bharat B Aggarwal, Haruyo Ichikawa, Prachi Garodia, Priya Weerasinghe, Gautam Sethi, Indra D Bhatt, Manoj K Pandey, Shishir Shishodia and Muraleedharan G Nair. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin. Ther. Targets 2006; 10:87-118.

4. Al-Sereiti MR, Abu-Amer KM and Sen P. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J Exp Biol. 1999; 37:124-30.

5. Ozlem Yesil-Celiktas, Canan Seviml, Erdal Bedir and Fazilet Vardar-Sukan. Inhibitory Effects of Rosemary Extracts, Carnosic Acid and Rosmarinic Acid on the Growth of Various Human Cancer Cell Lines. Plant Foods Hum Nutr. 2010; 65:158–163.

6. Julia Bauer, Susanne Kuehnl, Judith M. Rollinger, Olga Scherer, Hinnak Northoff, Hermann Stuppner, Oliver Werz, and Andreas Koeberle. Carnosol and carnosic acids from Salvia officinalis inhibit microsomal prostaglandin E2 synthase-1. JPET Fast Forward. 2012; 1-35

7. Jeremy J. Johnson. Carnosol: a promising anti-cancer and anti-inflammatory agent. Cancer Lett 2011; 305:1-7.

8. Ho C T, Wang M, Wei GJ, Huang TC and Huang MT. Chemistry and antioxidative factors in rosemary and sage. Biofactors. 2000; 13:161-6

9. Ngo SN, Williams DB and Head RJ. Rosemary and cancer prevention: preclinical perspectives. Crit Rev Food Sci Nutr. 2011; 51:946-54.

10. Einbond LS, Wu HA, Kashiwazaki R, He K, Roller M, Su T, Wang X and Goldsberry S. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin. Fitoterapia. 2012; 83:1160-8.

11. Valdés A, García Cañas V, Rocamora Reverte L, Gómez Martínez A, Ferragut JA and Cifuentes A. Effect of rosemary polyphenols on human colon cancer cells: transcriptomic profiling and functional enrichment analysis. Genes Nutr. 2013; 8:43-60.

12. Tai J, Cheung S, Wu M and Hasman D. Antiproliferation effect of Rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro. Phytomedicine. 2012; 19:436-43.

13. Barni MV, Carlini MJ, Cafferata EG, Puricelli L and Moreno S. Carnosic acid inhibits the proliferation and migration capacity of human colorectal cancer cells. Oncol Rep. 2012; 27:1041-8.

14. López Jiménez A, García Caballero M, Medina MA, Quesada AR. Anti-angiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary. Eur J Nutr. 2011; 52:85-95.

15. Chen YZ and Ung CY. Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J. Mol. Graph. Model. 2001; 20:199–218

16. Li H, Gao Z, Kang L, Zhang H, Yang K, Yu K, Luo X, Zhu W, Chen K and Shen J. TarFisDock: A web server for identifying drug targets with docking approach. Nucleic Acids Res. 2006; 34:W219–W224.

17. Xiaofeng Liu, Sisheng Ouyang, Biao Yu, Kai Huang, Yabo Liu, Jiayu Gong, Sisuan Zheng, Zhihua Li, Honglin Li and Hualiang Jiang. PharmMapper Server: a web server for potential drug target identification via pharmacophore mapping approach. Nucl. Acids Res. 2010; 38:W609-W614.

18. Jui Chih Wang, Pei Ying Chu, Chung Ming Chen and Jung Hsin Lin. idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach. Nucl. Acids Res. 2012; 40:W393-W399.

19. Jean Luc Pons and Gilles Labesse. @TOME-2: a new pipeline for comparative modeling of protein–ligand complexes.Nucl. Acids Res. 2009; 37:W485-W491.

20. Rong Zheng, Tuan sheng Chen and Tun Lu. A Comparative Reverse Docking Strategy to Identify Potential Antineoplastic Targets of Tea Functional Components and Binding Mode; Int. J. Mol. Sci. 2011; 12: 5200-5212.

21. Poeckel D, Greiner C, Verhoff M, Rau O, Tausch L, Hörnig C, Steinhilber D, Schubert-Zsilavecz M and Werz O. Carnosic acid and carnosol potently inhibit human 5-lipoxygenase and suppress pro-inflammatory responses of stimulated human polymorphonuclear leukocytes. Biochem Pharmacol. 2008; 76:91-7.

22. Johnson JJ, Syed DN, Heren CR, Suh Y, Adhami VM and Mukhtar H. Carnosol, a dietary diterpene, displays growth inhibitory effects in human prostate cancer PC3 cells leading to G2-phase cell cycle arrest and targets the 5'-AMP-activated protein kinase (AMPK) pathway. Pharm Res. 2008; 25:2125-34

23. Smoak KA and Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev. 2004; 125:697-706.

24. Hayes JD and Pulford DJ, The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995; 30:445-600.

25. Johnson JJ, Syed DN, Suh Y, Heren CR, Saleem M, Siddiqui IA and Mukhtar H. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer Prev Res. 2010;.3:1112-23.

26. Kotha Subbaramaiah, Philip A Cole and Andrew J. Dannenberg. Retinoids and Carnosol Suppress Cyclooxygenase-2 Transcription by CREB-binding Protein/p300-dependent and independent Mechanisms. Cancer Res. 2002; 62:2522.

27. Reisdorph R and Lindahl R. Constitutive and 3-methylcholanthrene-induced rat ALDH3A1 expression is mediated by multiple xenobiotic response elements. Drug Metab Dispos. 2007; 35:386-93.

28. Li R, Bianchet MA, Talalay P and Amzel LM. The three-dimensional structure of NAD (P) H: quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. PNAS. 1995; 92: 8846-8850.

29. Eric C Griffith, Zhuang Su, Benjamin E Turk, Shaoping Chen, Yie Hwa Chang, Zhuchun Wu, Klaus Biemann and Jun O Liu. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chemistry & Biology. 1997; 4:461–471.

30. Nomura T and Katunuma N. "Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells". J. Med. Invest. 2005; 52:1–9.

31. Chantong B, Kratschmar DV, Nashev LG, Balazs Z and Odermatt A.Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells. J Neuroinflammation. 2012; 28:260.

32. Qian Huang, Fang Li, Xinjian Liu, Wenrong Li, Wei Shi, Fei-Fei Liu, Brian O'Sullivan, Zhimin He, Yuanlin Peng, Aik-Choon Tan, Ling Zhou, Jingping Shen, Gangwen Han, Xiao-Jing Wang, Jackie Thorburn, Andrew Thorburn, Antonio Jimeno, David Raben, Joel S Bedford and Chuan Yuan Li. Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine. 2011; 17:860–866.

33. Jane Trepe., Mehdi Mollapou., Giuseppe Giaccone and Len Neckers. Targeting the dynamic HSP90 complex in cancer. Nature Reviews Cancer. 2010; 10: 537-549.

34. Goldberg Z, Vogt Sionov Ronit, Berger Michael, Zwang Yaara, Perets Ruth, Van Etten Richard A, Oren Moshe, Taya Yoichi and Haupt Ygal. "Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation". EMBO J. 2002; 21:3715–27.

35. Bagga V, Silakari O, Ghorela VS, Bahia MS, Rambabu G and Sarma J. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for

novel inhibitors. SAR QSAR Environ Res. 2011; 22:171-90.

36. Qiang Song Tong, Li Duan Zheng, Liang Wang, Fu Qing Zeng, Fang Min Chen, Ji-Hua Dong and Gong-Cheng Lu.Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Therapy. 2005; 12:509–514.

37. Albert M., Helin K. Histone methyltransferases in cancer. Semin Cell Dev Biol 2010; 21:209-20.

38. Duncan TJ, Al Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I and Durrant LG. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res. 2008; 14:3030-5.

39. Ottenhoff-Kalff AE, Rijksen G, Van Beurden EACM, Hennipman A, Michels A. A and Staal GEJ. Characterization of Protein Tyrosine Kinases from Human Breast Cancer:Involvement of the c-src Oncogene Product1. Cancer Res. 1992; 52:4773-4778.

40. Hsiang Yu Lin, Chang Shi Chen, Shuan Pei Lin, Jing Ru Weng and Ching Shih Chen. Targeting histone deacetylase in cancer therapy. Medicinal Research Reviews. 2006; 26:397–413.

41. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004; 64:1444-51.

42. Yam CH, Fung TK and Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002; 59:1317-26.

**\*Corresponding Author:**
**SAVITA DESHMUKH**
Department of Bioinformatics,
Karnataka State Women's University,
Bijapur-586108, Karnataka, INDIA.